Vitamin K2 covalently binds to bak and induces bak-mediated apoptosiss

Molecular Pharmacology

Volumn 83, Issue 3, 2013, Pages 613-620

  Karasawa, Satoki ^a   Azuma, Motoki ^c   Kasama, Takeshi ^a   Sakamoto, Satoshi ^a   Kabe, Yasuaki ^a   Imai, Takeshi ^a   Yamaguchi, Yuki ^a   Miyazawa, Keisuke ^d   Handa, Hiroshi ^a,b  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME C; FARNOQUINONE; MITOCHONDRIAL PROTEIN; PROTEIN BAK; PROTEIN BAX; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; COVALENT BOND; DRUG PROTEIN BINDING; DRUG TARGETING; HELA CELL; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CELL DEATH; CELL LINE, TUMOR; CYSTEINE; CYTOCHROMES C; HELA CELLS; HL-60 CELLS; HUMANS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; VITAMIN K 2;

EID: 84874324746     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.082602     Document Type: Article

References (44)

1. Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M, Furihata M, Kamatani N, Inazawa J, and Chen GK et al. (2012) Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet 44:426-429, S1.
2. Dam H (1929) Cholesterinstoffwechsel in hühnereiern und hähnchen Biochem Z 215: 475-492.
3. Dam H (1935) The antihaemorrhagic vitamin of the chick. Biochem J 29:1273-1285.
4. Fox JL, Ismail F, Azad A, Ternette N, Leverrier S, Edelmann MJ, Kessler BM, Leigh IM, Jackson S, and Storey A (2010) Tyrosine dephosphorylation is required for Bak activation in apoptosis. EMBO J 29:3853-3868.
5. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, and Hemken PM et al. (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29:909-916.
6. Gavathiotis E, Reyna DE, Bellairs JA, Leshchiner ES, and Walensky LD (2012) Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol 8:639-645.
7. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, and Nishiguchi S (2004) Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 292:358-361. (Pubitemid 38944260)
8. Hase Y, Tatsuno M, Nishi T, Kataoka K, Kabe Y, Yamaguchi Y, Ozawa N, Natori M, Handa H, and Watanabe H (2008) Atrazine binds to F1F0-ATP synthase and inhibits mitochondrial function in sperm. Biochem Biophys Res Commun 366:66-72. (Pubitemid 350297218)
9. Hauschka PV, Lian JB, and Gallop PM (1975) Direct identification of the calciumbinding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA 72:3925-3929.
10. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, and Inoue S (2006) Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem 281:16927-16934.
11. Inoue T, Kato K, Kato H, Asanoma K, Kuboyama A, Ueoka Y, Yamaguchi S, Ohgami T, and Wake N (2009) Level of reactive oxygen species induced by p21Waf1/CIP1 is critical for the determination of cell fate. Cancer Sci 100:1275-1283.
12. Ishii M, Shimomura M, Hasegawa J, Morishita N, Nakai H, Kayano M, Kurimoto T, Harada H, Tsuji S, and Aoki T et al. (1992) Evaluation of pharmacokinetics and bioequivalence of soft capsules of menatetrenone. J Clin Therap Med 8:571-585.
13. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, and Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
14. Iwamoto J, Takeda T, and Sato Y (2004) Effects of vitamin K2 on osteoporosis. Curr Pharm Des 10:2557-2576. (Pubitemid 38997434)
15. Knudson CM, Tung KS, Tourtellotte WG, Brown GA, and Korsmeyer SJ (1995) Baxdeficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96-99.
16. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, and Schlesinger PH (2000) Proapoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7:1166-1173. (Pubitemid 32042223)
17. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, and Frauwirth K et al. (2000) The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6:1389-1399. (Pubitemid 32045931)
18. Matsumoto K, Okano J, Nagahara T, and Murawaki Y (2006) Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int J Oncol 29: 1501-1508.
19. Matsura T, Serinkan BF, Jiang J, and Kagan VE (2002) Phosphatidylserine peroxidation/externalization during staurosporine-induced apoptosis in HL-60 cells. FEBS Lett 524:25-30. (Pubitemid 34804829)
20. Miyazawa K, Nishimaki J, Ohyashiki K, Enomoto S, Kuriya S, Fukuda R, Hotta T, Teramura M, Mizoguchi H, and Uchiyama T et al. (2000) Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: Information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia 14:1156-1157. (Pubitemid 30389524)
21. Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, and Yamamoto K (2006) The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: A pilot study. Cancer 106:867-872. (Pubitemid 43238454)
22. Nakazato T, Sagawa M, Yamato K, Xian M, Yamamoto T, Suematsu M, Ikeda Y, and Kizaki M (2007) Myeloperoxidase is a key regulator of oxidative stress mediated apoptosis in myeloid leukemic cells. Clin Cancer Res 13:5436-5445. (Pubitemid 47510371)
23. Nishi T, Shimizu N, Hiramoto M, Sato I, Yamaguchi Y, Hasegawa M, Aizawa S, Tanaka H, Kataoka K, and Watanabe H et al. (2002) Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J Biol Chem 277:44548-44556. (Pubitemid 36157890)
24. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, and Cheson BD (2009) Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113:299-305.
25. Oldenburg J, Marinova M, Müller-Reible C, and Watzka M (2008) The vitamin K cycle. Vitam Horm 78:35-62.
26. Otsuka M, Kato N, Ichimura T, Abe S, Tanaka Y, Taniguchi H, Hoshida Y, Moriyama M, Wang Y, and Shao RX et al. (2005) Vitamin K2 binds 17beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Life Sci 76:2473-2482. (Pubitemid 40341963)
27. Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, and Handa H (2009) Development and application of high-performance affinity beads: Toward chemical biology and drug discovery. Chem Rec 9:66-85.
28. Sano Y, Tadano K, Kaneko K, Kikuchi K, and Yuzuriha T (1995) Distribution of menaquinone-4, a therapeutic agent for osteoporosis, in bone and other tissues of rats. J Nutr Sci Vitaminol (Tokyo) 41:499-514.
29. Sano Y, Tadano K, Kaneko K, Kikuchi K, and Yuzuriha T (1997) Metabolic fate of manaquinone-4 in dogs (I): Absorption, distribution, metabolism and excretion after a single oral administration. Xenobio Metabol Dispos 12:48-57.
30. Seegers WH and Bang NU (1967) Blood Clotting Enzymology, Academic Press, New York.
31. Shibayama-Imazu T, Sonoda I, Sakairi S, Aiuchi T, Ann WW, Nakajo S, Itabe H, and Nakaya K (2006) Production of superoxide and dissipation of mitochondrial transmembrane potential by vitamin K2 trigger apoptosis in human ovarian cancer TYK-nu cells. Apoptosis 11:1535-1543. (Pubitemid 44253671)
32. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M, Aizawa S, Hatakeyama M, Ohba R, and Hatori H et al. (2000) High-performance affinity beads for identifying drug receptors. Nat Biotechnol 18:877-881. (Pubitemid 30640915)
33. Stafford DW (2005) The vitamin K cycle. J Thromb Haemost 3:1873-1878. (Pubitemid 41716574)
34. Suhara Y, Hirota Y, Nakagawa K, Kamao M, Tsugawa N, and Okano T (2008) Design and synthesis of biologically active analogues of vitamin K2: Evaluation of their biological activities with cultured human cell lines. Bioorg Med Chem 16: 3108-3117. (Pubitemid 351418194)
35. Tabb MM, Sun A, Zhou C, Grün F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, and Lin M et al. (2003) Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919-43927. (Pubitemid 37377131)
36. Thorp JA, Gaston L, Caspers DR, and Pal ML (1995) Current concepts and controversies in the use of vitamin K. Drugs 49:376-387.
37. Tokita H, Tsuchida A, Miyazawa K, Ohyashiki K, Katayanagi S, Sudo H, Enomoto M, Takagi Y, and Aoki T (2006) Vitamin K2-induced antitumor effects via cell-cycle arrest and apoptosis in gastric cancer cell lines. Int J Mol Med 17:235-243.
38. Tsujioka T, Miura Y, Otsuki T, Nishimura Y, Hyodoh F, Wada H, and Sugihara T (2006) The mechanisms of vitamin K2-induced apoptosis of myeloma cells. Haematologica 91:613-619. (Pubitemid 43799455)
39. Ushiroyama T, Ikeda A, and Ueki M (2002) Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 41:211-221. (Pubitemid 34211976)
40. Watanabe D, Yamamoto A, Tomoo K, Matsumoto K, Murata M, Kitamura K, and Ishida T (2006) Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes. J Mol Biol 362:979-993. (Pubitemid 44382692)
41. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, and Korsmeyer SJ (2000) tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 14:2060-2071. (Pubitemid 30637355)
42. Westhofen P, Watzka M, Marinova M, Hass M, Kirfel G, Müller J, Bevans CG, Müller CR, and Oldenburg J (2011) Human vitamin K 2,3-epoxide reductase complex subunit 1-like 1 (VKORC1L1) mediates vitamin K-dependent intracellular antioxidant function. J Biol Chem 286:15085-15094.
43. Yaguchi M, Miyazawa K, Otawa M, Ito Y, Kawanishi Y, and Toyama K (1999) Vitamin K2 therapy for a patient with myelodysplastic syndrome. Leukemia 13:144-145. (Pubitemid 29043731)
44. Yokoyama T, Miyazawa K, Naito M, Toyotake J, Tauchi T, Itoh M, Yuo A, Hayashi Y, Georgescu MM, and Kondo Y et al. (2008) Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy 4:629-640.